FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307831196> ?p ?o ?g. }

• W4307831196 abstract "Tumour hypoxia is a known and extensively researched phenomenon that occurs in both solid and haematological malignancies. As cancer cells proliferate, demand for oxygen can outstrip supply reducing tumour oxygenation. In solid tumours this is contributed to by disorganized blood vessel development. Tumour hypoxia is associated with resistance to treatment, more aggressive disease behaviour and an increased likelihood of metastatic progression. It can be measured using both invasive and non-invasive methods to varying degrees of accuracy. The presence of hypoxia stimulates a complex cellular network of downstream factors including Hypoxia Inducible Factor 1 (HIF1), C-X-C motif chemokine 4 (CXCR4) and Hypoxia-inducible glycolytic enzyme hexokinase-2 (HK2) amongst many others. They work by affecting different mechanisms including influencing angiogenesis, treatment resistance, immune surveillance and the ability to metastasize all of which contribute to a more aggressive disease pattern. Tumour hypoxia has been correlated with poorer outcomes and worse prognosis in patients. The correlation between hypoxic microenvironments and poor prognosis has led to an interest in trying to therapeutically target this phenomenon. Various methods have been used to target hypoxic microenvironments. Hypoxia-activated prodrugs (HAPs) are drugs that are only activated within hypoxic environments and these agents have been subject to investigation in several clinical trials. Drugs that target downstream factors of hypoxic environments including HIF inhibitors, mammalian target of rapamycin (mTOR) inhibitors and vascular endothelial growth factor (anti-VEGF) therapies are also in development and being used in combination in clinical trials. Despite promising pre-clinical data, clinical trials of hypoxia targeting strategies have proven challenging. Further understanding of the effect of hypoxia and related molecular mechanisms in human rather than animal models is required to guide novel therapeutic strategies and future trial design. This review will discuss the currently available methods of hypoxia targeting and assessments that may be considered in planning future clinical trials. It will also outline key trials to date in both the solid and haemato-oncology treatment spheres and discuss the limitations that may have impacted on clinical success to date." @default.
• W4307831196 created "2022-11-06" @default.
• W4307831196 creator A5025973718 @default.
• W4307831196 creator A5032366727 @default.
• W4307831196 creator A5051058379 @default.
• W4307831196 creator A5070242435 @default.
• W4307831196 date "2022-11-02" @default.
• W4307831196 modified "2023-10-14" @default.
• W4307831196 title "Targeting hypoxia in solid and haematological malignancies" @default.
• W4307831196 cites W1491348262 @default.
• W4307831196 cites W1553189280 @default.
• W4307831196 cites W1868704956 @default.
• W4307831196 cites W1932804803 @default.
• W4307831196 cites W1962692964 @default.
• W4307831196 cites W1965136308 @default.
• W4307831196 cites W1965659514 @default.
• W4307831196 cites W1966381192 @default.
• W4307831196 cites W1966798186 @default.
• W4307831196 cites W1967532587 @default.
• W4307831196 cites W1968192372 @default.
• W4307831196 cites W1969330686 @default.
• W4307831196 cites W1975071040 @default.
• W4307831196 cites W1975889523 @default.
• W4307831196 cites W1977328011 @default.
• W4307831196 cites W1980649340 @default.
• W4307831196 cites W1981207410 @default.
• W4307831196 cites W1981487137 @default.
• W4307831196 cites W1983486852 @default.
• W4307831196 cites W1989177534 @default.
• W4307831196 cites W1990923495 @default.
• W4307831196 cites W1994767036 @default.
• W4307831196 cites W1998664010 @default.
• W4307831196 cites W2000562291 @default.
• W4307831196 cites W2000610587 @default.
• W4307831196 cites W2001150802 @default.
• W4307831196 cites W2011925011 @default.
• W4307831196 cites W2012390829 @default.
• W4307831196 cites W2014245338 @default.
• W4307831196 cites W2014292477 @default.
• W4307831196 cites W2015157460 @default.
• W4307831196 cites W2015395053 @default.
• W4307831196 cites W2017565497 @default.
• W4307831196 cites W2017619966 @default.
• W4307831196 cites W2018172463 @default.
• W4307831196 cites W2020021293 @default.
• W4307831196 cites W2029206767 @default.
• W4307831196 cites W2035782306 @default.
• W4307831196 cites W2038543378 @default.
• W4307831196 cites W2042075770 @default.
• W4307831196 cites W2043702533 @default.
• W4307831196 cites W2045945310 @default.
• W4307831196 cites W2050056000 @default.
• W4307831196 cites W2050446445 @default.
• W4307831196 cites W2052401940 @default.
• W4307831196 cites W2053470746 @default.
• W4307831196 cites W2054719244 @default.
• W4307831196 cites W2055715830 @default.
• W4307831196 cites W2057366549 @default.
• W4307831196 cites W2057742754 @default.
• W4307831196 cites W2061478772 @default.
• W4307831196 cites W2064695479 @default.
• W4307831196 cites W2067680442 @default.
• W4307831196 cites W2068141056 @default.
• W4307831196 cites W2068353461 @default.
• W4307831196 cites W2071062200 @default.
• W4307831196 cites W2072642889 @default.
• W4307831196 cites W2073325028 @default.
• W4307831196 cites W2077245360 @default.
• W4307831196 cites W2082239705 @default.
• W4307831196 cites W2084939996 @default.
• W4307831196 cites W2087377825 @default.
• W4307831196 cites W2094206434 @default.
• W4307831196 cites W2094300507 @default.
• W4307831196 cites W2097429307 @default.
• W4307831196 cites W2101911974 @default.
• W4307831196 cites W2103794392 @default.
• W4307831196 cites W2108949570 @default.
• W4307831196 cites W2109424201 @default.
• W4307831196 cites W2111176717 @default.
• W4307831196 cites W2112003796 @default.
• W4307831196 cites W2115307642 @default.
• W4307831196 cites W2117692326 @default.
• W4307831196 cites W2119010359 @default.
• W4307831196 cites W2120683750 @default.
• W4307831196 cites W2121263831 @default.
• W4307831196 cites W2121669013 @default.
• W4307831196 cites W2124496728 @default.
• W4307831196 cites W2128650300 @default.
• W4307831196 cites W2129321174 @default.
• W4307831196 cites W2132217314 @default.
• W4307831196 cites W2135687519 @default.
• W4307831196 cites W2136579332 @default.
• W4307831196 cites W2137210843 @default.
• W4307831196 cites W2137371083 @default.
• W4307831196 cites W2138425716 @default.
• W4307831196 cites W2140741923 @default.
• W4307831196 cites W2142619483 @default.
• W4307831196 cites W2146639342 @default.
• W4307831196 cites W2150322923 @default.
• W4307831196 cites W2155461218 @default.

• next